Amylyx Pharmaceuticals (NASDAQ:AMLX) Earns “Buy” Rating from HC Wainwright

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $55.00 target price on the stock. HC Wainwright‘s price objective would indicate a potential upside of 106.61% from the company’s previous close.

A number of other equities analysts also recently commented on AMLX. Guggenheim raised their price objective on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a report on Thursday, August 27th. Citigroup upped their target price on shares of Amylyx Pharmaceuticals from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, October 15th. Robert W. Baird increased their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 19th. Stifel Nicolaus set a $45.00 price target on shares of Amylyx Pharmaceuticals in a research note on Thursday, November 5th. Finally, Mizuho raised their price target on shares of Amylyx Pharmaceuticals from $38.00 to $39.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Amylyx Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $43.71.

Get Our Latest Stock Analysis on Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $26.62 on Thursday. The stock has a market cap of $3.42 billion, a P/E ratio of -18.49 and a beta of -0.09. Amylyx Pharmaceuticals has a one year low of $10.83 and a one year high of $41.14. The stock has a fifty day moving average price of $29.28 and a 200 day moving average price of $20.97.

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.38). Equities research analysts anticipate that Amylyx Pharmaceuticals will post -1.50 EPS for the current year.

Insider Buying and Selling

In other news, Director George M. Milne, Jr. sold 30,000 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $27.70, for a total value of $831,000.00. Following the sale, the director owned 782,881 shares of the company’s stock, valued at approximately $21,685,803.70. This represents a 3.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Camille L. Bedrosian sold 10,028 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $32.40, for a total transaction of $324,907.20. Following the sale, the insider owned 278,064 shares of the company’s stock, valued at $9,009,273.60. This trade represents a 3.48% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 60,374 shares of company stock valued at $1,815,257 in the last ninety days. Insiders own 10.90% of the company’s stock.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth approximately $158,534,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Amylyx Pharmaceuticals by 10.4% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 173,407 shares of the company’s stock valued at $3,114,000 after acquiring an additional 16,318 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $705,000. Elmind Capital LP acquired a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $2,011,520. Finally, Nantahala Capital Management LLC acquired a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $8,740,845. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

(Get Free Report)

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Featured Articles

Analyst Recommendations for Amylyx Pharmaceuticals (NASDAQ:AMLX)

Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.